...
机译:抗PD-1抗体在NSCLC患者患者抗折叠和高PD-L1表达中的疗效
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Expt Therapeut Tokyo Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Natl Canc Ctr Dept Thorac Oncol Chuo Ku 5-1-1 Tsukiji Tokyo 1040045 Japan;
Non-small cell lung cancer; Programmed death-ligand-1; Epidermal growth factor receptor; Immune checkpoint inhibitor;
机译:肾素–血管紧张素系统抑制剂对NSCLC患者抗PD-1 / PD-L1抗体疗效的影响
机译:抗PD-1 / PD-L1药物治疗的NSCLC患者PD-L1表达与预后的相关性:荟萃分析
机译:EML4-ALK融合蛋白对PD-L1的上调介导ALK阳性NSCLC的免疫逃逸:对ALK-TKIs敏感和耐药NSCLC患者的可选抗PD-1 / PD-L1免疫疗法的意义
机译:FFPE NSCLC样品中PD-L1蛋白的定量质谱测定的开发和临床验证
机译:基质刚性对肺癌细胞中PD-L1表达的调节
机译:抗PD-1 / PD-L1抗体疗法与多西紫杉醇对预处理的晚期NSCLC的疗效和安全性:一项荟萃分析
机译:肿瘤PD-L1表达加CD4或CD8 T细胞渗透的免疫谱与NSCLC患者PD-1阻断抗体的治疗疗效相关联
机译:放射性标记的赫赛汀增加低肿瘤HER-2 / neu表达的乳腺癌患者的治疗效果